会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • BENZAMIDE DERIVATIVES AS THROMBIN INHIBITORS
    • 苯扎林衍生物作为抑制剂
    • WO1997022589A1
    • 1997-06-26
    • PCT/EP1996005743
    • 1996-12-13
    • GLAXO GROUP LIMITEDWATSON, Nigel, StephenPASS, MartinPATEL, Vipulkumar
    • GLAXO GROUP LIMITED
    • C07D213/74
    • C07D213/74A61K31/4409A61K31/4439C07D401/12C07D405/12C07D417/12
    • The invention relates to a novel class of amide derivatives which act as thrombin inhibitors as described by formula (I), where R and R , independently represent a group (a) or R and R together form a C3-7 heterocycloalkyl or heterocycloalkenyl group which may be optionally substituted by C1-6 alkyl, C1-4 alkoxy, halogen, carboxylic acid or a C1-4 carboxylic acid ester group; R represents hydrogen, C1-3 alkyl, halogen, or C1-2 alkoxy; R , R and R independently represent hydrogen, or halogen; R represents hydrogen or C1-6 alkyl; R represents hydrogen, C3-7 cycloalkyl, C3-7 cycloalkenyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkenyl, aryl or heteroaryl, which groups are optionally substituted by one or more groups selected from halogen, hydroxy, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 acyloxy, NR R , NHCOR , NHSO2R , COR , CO2R , CONR R , and SO2NHR ; X represents a bond, a C1-6 alkyl chain, or a C3-6 alkenyl chain, where one or two nitrogen, oxygen, or sulfur atoms may be optionally contained within each chain, and the chains are optionally substituted by one or more groups selected from halogen, hydroxy, CN, C1-6alkyl, C1-6alkoxy, C1-6acyloxy, NR R , NHCOR , NHSO2R , COR , CO2R , CONR R , and SO2NHR ; R -R represent hydrogen, C1-6 alkyl, or R and R or R and R form a C3-7 heterocycloalkyl ring, or R additionally may represent trifluoromethyl; and pharmaceutically acceptable derivatives or solvates threreof, to processes for their preparation; and their use in the treatment of clinical conditions susceptible to amelioration by administration of a thrombin inhibitor.
    • 本发明涉及作为如式(I)所述的凝血酶抑制剂的新一类酰胺衍生物,其中R 1和R 2独立地表示基团(a)或R 1和R 2 >一起形成可以被C 1-6烷基,C 1-4烷氧基,卤素,羧酸或C 1-4羧酸酯基团任选取代的C 3-7杂环烷基或杂环烯基; R 3表示氢,C 1-3烷基,卤素或C 1-2烷氧基; R 4,R 5和R 6独立地表示氢或卤素; R 7表示氢或C 1-6烷基; R 8表示氢,C 3-7环烷基,C 3-7环烯基,C 3-7杂环烷基,C 3-7杂链烯基,芳基或杂芳基,这些基团任选被一个或多个选自卤素,羟基,CN,C 1 -6烷基,C 1-6烷氧基,C 1-6酰氧基,NR 9 R 10,NHCOR 11,NHSO 2 R 12,COR 13,CO 2 R 14,CONR 15 R 16 >和SO2NHR17; X表示键,C 1-6烷基链或C 3-6烯基链,其中每个链中可任选地含有一个或两个氮,氧或硫原子,并且该链任选被一个或多个基团取代 选自卤素,羟基,CN,C 1-6烷基,C 1-6烷氧基,C 1-6酰氧基,NR 9 R 10,NHCOR 11,NHSO 2 R 12,COR 13,CO 2 R 14,CONR <15> R 16,和SO 2 NHR 17; R 9 -R 17代表氢,C 1-6烷基或R 9和R 10或R 15和R 16形成C 3-7杂环烷基环,或R 12 另外可以表示三氟甲基; 和其药学上可接受的衍生物或溶剂合物,用于制备它们的方法; 以及它们在治疗通过施用凝血酶抑制剂而易于改善的临床病症中的用途。
    • 7. 发明申请
    • PYRIMIDINONE DERIVATIVES
    • 吡咯烷酮衍生物
    • WO1986001205A1
    • 1986-02-27
    • PCT/GB1985000360
    • 1985-08-13
    • GLAXO GROUP LIMITEDPHILLIPPS, Gordon, HanleyUNDHEIM, KjellWILLIAMSON, ChristopherSTEEPLES, Ian, PhilipBAIN, Brian, MacDonaldBORELLA, Raymond, Andrew
    • GLAXO GROUP LIMITED
    • C07D239/22
    • C07D239/56C07D409/06C07D417/06
    • Bisulphite adducts of compounds of formula (I) wherein R represents a group formula (II), R represents a halogen atom or a trifluoromethyl group; R represents a hydrogen atom or a C1-4 alkyl, C6-10 aryl or benzoyl group; R represents a hydrogen atom or, together with R , represents a -CH2- or -CH2-CH2- chain; and formula (III) represents a C6-10 carbocyclic aromatic group or a carbon-attached heterocyclic group containing a 5- or 6- membered unsaturated heterocyclic ring which ring contains one or more heteroatoms selected from O, N and S and optionally carries a fused carbocyclic ring, which carbocyclic or heterocyclic group may carry one or more substituents selected from halogen atoms, C1-4 alkyl, C1-4 alkanoyl, C1-4 alkoxy, C1-4 alkoxycarbonyl, C1-4 alkylthio, hydroxyl, nitro, cyano and formyl groups, -NR R groups (where R is a hydrogen atom or a C1-4 alkyl group, and R is a hydrogen atom or a C1-4 alkyl, C1-4 alkanoyl or aroyl group) and C1-4 alkyl groups substituted by one or more hydroxy or -NR R groups and halogen atoms; and salts of such adducts have metaphase arrest abilities and desirably good water solubilities and may be useful in combatting abnormal cell proliferation.
    • 式(I)化合物的亚硫酸氢盐加合物,其中R表示基团式(II),R 1表示卤素原子或三氟甲基; R 2表示氢原子或C 1-4烷基,C 6-10芳基或苯甲酰基; R 3表示氢原子,或与R 2一起代表-CH 2 - 或-CH 2 -CH-链; 并且式(III)表示含有5-或6-元不饱和杂环的C 6-10碳环芳基或含碳连接的杂环基,该环含有一个或多个选自O,N和S的杂原子,并且任选携带稠合 碳环,其中碳环或杂环基可以携带一个或多个选自卤素原子,C 1-4烷基,C 1-4烷酰基,C 1-4烷氧基,C 1-4烷氧基羰基,C 1-4烷硫基,羟基,硝基,氰基和 甲酰基,-NR 4 R 5基团(其中R 4是氢原子或C 1-4烷基,R 5是氢原子或C 1-4烷基,C 1-4 烷酰基或芳酰基)和被一个或多个羟基或-NR 4 R 5基团和卤素原子取代的C 1-4烷基; 并且这种加合物的盐具有中期阻滞能力和期望的良好的水溶性,并且可用于对抗异常细胞增殖。